In March 2023, Japan’s Ministry of Health and Labor Welfare approved Novo Nordisk’s once-weekly subcutaneous glucagon-like peptide-1
CMOs showed an increasing reluctance to take on debt in 2022
Approval to dramatically change CAR-T therapies landscape
The positive safety review from the DSMB enables the trial to move forward as planned, with an estimated completion date in December 2023
Decisions on the marketing authorization for Rystiggo in the European and Japanese markets are expected in Q1 of 2024
Pfizer is likely to show GSK significant competition
The judicial response to industry lawsuits on drug pricing regulations have been mixed in the past
The drug exhibited greater treatment persistence and control of moderate-to-severe PsO symptoms compared to secukinumab and ixekizumab
Farxiga is expected to have such a strong influence on the market due to the impressive results
Brexit had a negative impact on NHS staff shortages and worsened the workforce crisis
Subscribe To Our Newsletter & Stay Updated
_256_275.jpg)